Posted by Michael Wonder on 10 Nov 2018
NICE says no to expanding use of AstraZeneca's’ Lynparza
9 November 2018 - NICE has ruled against expanding use of AstraZeneca’s Lynparza to a wider patient population with ovarian cancer.
The drug’s recent expanded approval in Europe allows its use for maintenance treatment of relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, that is in response to platinum-based chemotherapy, in adults regardless of BRCA status.
In an appraisal consultation document, the Institute said clinical trials show that while Lynparza (olaparib; pill formulation) extends the time until cancer progresses compared with routine surveillance, it is not cost effective in this setting.
